Vision-threatening uveitis of unknown origin

Article

What to investigate: aqueous, vitreous or both?

The main advantage of diagnostic vitrectomy is obviously a larger volume of sample which allows a more thorough analysis and multiple investigations in one sample. In addition, vitrectomy may improve visual acuity, but its drawback is its invasiveness, possibility of adverse effects and higher costs.

In contrast, aqueous analysis is a less invasive procedure and may yield results faster. However, an aqueous tap provides a restricted volume of the sample (usually around 100–200 microlitres) and, therefore, allows only a limited number of examinations.

Conversely, outside Europe, diagnostic vitrectomy is frequently being performed as a primary surgical diagnostic procedure, and the acquired material is being assessed by PCR and other various methods including microbial cultures, cytology, immunophenotyping by flow cytometry and other examinations, usually based on clinical manifestations of the patients.

GWC is a more elaborate diagnostic assay than PCR and is, therefore, not universally used. Obviously, the simultaneous analyses of vitreous sample provide the most valuable assessment and prevent the need for multiple diagnostic interventions, but may limit the volume of separate samples. The diagnostic value of vitrectomy varies widely, which is certainly caused by the number of examinations performed with a given sample and by the selection of patients. The selection based on a clinical suspicion of specific diagnosis increases the positive outcome of a diagnostic procedure.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
© 2025 MJH Life Sciences

All rights reserved.